NEW YORK, Oct. 19 (UPI) -- The German pharmaceutical company Bayer HealthCare plans tests to determine if its newest antibiotic is effective against tuberculosis.
The New York Times said that no new drugs against tuberculosis have been registered in 40 years. Most drug companies do not test patented pharmaceuticals against diseases associated with poverty.
Bayer said that if moxifloxacin shortens TB treatment it will provide millions of doses for poor countries.
The trials are being funded by the Bill and Melinda Gates Foundation and by the Centers for Disease Control and Prevention, the new European and Developing Countries Clinical Trials Partnership and the Food and Drug Administration.